生物医药系列产品
数据
资源
版本对比
免费注册
预约演示
免费注册
Gilead
stops last PhIII of
CD47 drug
, citing FDA hold, higher risk of death in treatment arm
2024-02-07
·
EndPoints
临床3期
临床终止
临床2期
Gilead
discontinued its remaining Phase III study of
magrolimab
, an
anti-CD47 antibody
that the company was testing for
acute myeloid leukemia
and its precursor disease, and it will not pursue future work on this therapy in
blood cancers
.
In an interim analysis, patients who received
magrolimab
had an increased risk of death compared to those who received standard care with
AbbVie
and
Roche
’s
Venclexta
and
azacitidine
.
Gilead
said Wednesday that the increased risk was “primarily driven by
infections
and
respiratory failure
.”
Preview
来源: EndPoints
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
SIGN UP
LOG IN
BECOME A PREMIUM SUBSCRIBER
更多内容,
请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点,如有版权侵扰或错误之处,请及时联系我们,我们会在24小时内配合处理。
机构
Gilead Sciences, Inc.
AbbVie, Inc.
Roche Holding AG
适应症
急性髓性白血病
血液肿瘤
感染
[+1]
靶点
-
药物
Anti-CD47 (InnoBation Bio)
莫洛利单抗
CD47单抗(智翔金泰)
[+2]
标准版
¥
16800
元/账号/年
新药情报库 | 省钱又好用!
立即使用
来和芽仔聊天吧
热门报告
特应性皮炎深度解析:药物开发、专利分析与风险评估
智慧芽生物医药
2024年7月全球首批及特殊审评药物报告
智慧芽生物医药
GPRC5D靶点专利调研报告
智慧芽生物医药
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台,助您全方位提升您的研发与决策效率。
开始免费试用
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台,以API或者数据包形式对外开放,助您更加充分利用智慧芽新药情报信息。
试用数据服务